Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930239 | 0.93 | MAOB (0.45) | MAOBKCNH2MAOACYP2C19PDE10A | |
| SCHEMBL14069348 | 0.90 | MAOB (0.38) | MAOBKCNH2MAOACYP2C19PDE10A | |
| SCHEMBL9968662 | 0.90 | KCNH2 (0.43) | MAOBKCNH2MAOACYP2C19PDE10A | |
| SCHEMBL9968660 | 0.88 | MAOB (0.48) | MAOBKCNH2MAOACYP2C19PDE10A | |
| SCHEMBL9930458 | 0.85 | MAOB (0.36) | MAOBKCNH2MAOAPDE10ACYP11B1 | |
| SCHEMBL9968481 | 0.84 | MAOB (0.38) | MAOBKCNH2MAOACYP2C19 | |
| SCHEMBL14069340 | 0.84 | MAOA (0.41) | MAOA | |
| SCHEMBL9930143 | 0.84 | MAOA (0.41) | MAOA | |
| SCHEMBL13429591 | 0.83 | KCNH2 (0.42) | KCNH2PDE10ACYP11B1CYP11B2 | |
| SCHEMBL4436007 | 0.83 | KCNH2 (0.45) | MAOBKCNH2MAOACYP2C19PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | MAOB 761/4885KCNH2 1295/4885MAOA 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.